Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315614 | 0.88 | TRPV1 (0.71) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL1979817 | 0.88 | TRPV1 (0.69) | TRPV1CYP3A4CYP2D6KDM4EALDH1A1 | |
| SCHEMBL1981386 | 0.88 | TRPV1 (0.71) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL1979979 | 0.86 | TRPV1 (0.69) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL1985332 | 0.84 | TRPV1 (0.55) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL2319927 | 0.84 | TRPV1 (0.69) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL1982255 | 0.81 | TRPV1 (0.71) | TRPV1CYP3A4 | |
| SCHEMBL2320518 | 0.81 | TRPV1 (1.00) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL2319990 | 0.81 | TRPV1 (1.00) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL3358957 | 0.81 | TRPV1 (0.65) | TRPV1CYP3A4CYP2D6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| EP-2352726-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | claimed |
| EP-2352727-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | claimed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | claimed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | claimed |
| WO-2010045402-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | claimed |
| WO-2010045401-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | claimed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2352726-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2352727-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045401-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045402-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CYP3A4 1282/4885CYP2D6 878/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CYP3A4 1264/4885CYP2D6 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.